V Clinbio LLC has purchased 49.98% equity stake in Cellix Bio Pvt Ltd.

V Clinbio is a biopharmaceutical company, while Cellix Bio is a drug development organisation. Both companies are based in India.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The acquisition will enable V Clinbio to develop Synergix, a transformative pro-drug technology platform.

Medical technology company Proteomics International Laboratories Ltd has agreed to purchase 10% stake in drug development support services provider CPR Pharma Services Pty Ltd (CPR).

Proteomics International will issue four million fully paid ordinary shares for 10% of the fully diluted issued share capital of CPR, as part of the transaction.

The acquirer company has simultaneously entered a memorandum agreement with CPR to provide commercial opportunities for its Promarker technology.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.
“Devonian will acquire all the shares of Altius in exchange for 8,403,361 units of Devonia priced at $1.19 per subordinate share.”

The acquisition is scheduled to be complete by 5 March 2018 upon receiving approval from CPR shareholders.

Devonian Health Group Inc has agreed to purchase the entire issued and outstanding shares of Altius Healthcare Inc.

Devonian is a Canadian pharmaceutical company, while Altius is involved in the manufacturing, marketing, and distribution of branded and generic medicines.

Devonian will acquire all the shares of Altius in exchange for 8,403,361 units of Devonia priced at $1.19 per subordinate share.

Scheduled to be complete by March 2018, the acquisition will enable Devonian to improve its sales and marketing bench strength.